Absci
Absci is a biotechnology company specializing in drug discovery and development using artificial intelligence. They focus on creating biologics for various diseases, partnering with pharmaceutical companies to accelerate the development of innovative therapies. Their Integrated Drug Creation platform allows for rapid design and optimization of biologics, addressing the challenges of traditional drug development processes.
Headcount
Website visitors
Workforce
Headcount by location
- United States92%
- Switzerland4.4%
- Serbia3.8%
Split by department
- Engineering & R&D51%
- Healthcare14%
- Finance & Administration8.7%
- Founder, Owner & Executive3.6%
- Other22%
Seniority distribution
- Less than 5 years62%
- 5 to 10 years32%
- 10 to 20 years2.3%
- 20 to 30 years2.3%
- 30 years and more0.8%
Funding
Raised to date
- 24 Jun 2026Series Other$100.0MAdage Capital Management, Bvf Partners, L.P, Columbia Threadneedle Investments, Invus, Eli Lilly and Company, Redmile Group
- 21 Sep 2025Series Other$64.0MAmd
13 earlier rounds, with their terms and sources.
Investors
Gates FoundationBill & Melinda Gates Foundation is a not‑for‑profit private foundation headquartered in Seattle, US. It provides grant funding, research support, and partnership programs in global health, development, and education to governments, NGOs, research1,639United States
Eli Lilly and CompanyEli Lilly and Company is a global pharmaceutical and biotechnology leader headquartered in Indianapolis, US. It discovers, develops, manufactures, and markets prescription medicines across cardiometabolic, obesity, oncology, immunology and319United States
Perceptive AdvisorsPerceptive Advisors is an investment management firm specializing in the life sciences sector. They manage approximately $8 billion across various funds, focusing on providing capital solutions to innovative healthcare companies. Their clients244United States
MsdMerck & Co., Inc. is a global biopharmaceutical company that discovers, develops, manufactures and markets human medicines, vaccines and animal health products. It serves patients, healthcare providers, veterinarians, governments and NGOs worldwide235United States
Portfolio
Countries
- United States100%
Deal stage
- Company Acquisition100%
Deal size
- Unknown100%
Company size
- Unknown100%
Revenue
EBITDA
Revenue source: Public reported FY2025 (Stock exchange)
Recent news
- Absci to report business updates and third quarter 2026 financial and operating results on November 12, 2026.
- Absci (NASDAQ:ABSI) shares up 13.2% - should you Buy?
8 more articles, with their sources and categories.
Deal terms
What each deal was actually worth — valuation, revenue and EBITDA multiples, and the filings behind them
Portfolio companies
Every holding by name, with what was paid, when, and how each one has grown since
People
How the team has changed month by month — joiners, leavers and where the hiring is going
Connections
Who at your firm already knows someone here, and how warm the path is
The full Absci profile lives in Inven.
Your competitors are already on Inven
See how Inven turns hours of manual research into a single, structured workflow.